Life Sciences M&A

The life sciences M&A market continues to be reshaped by scientific breakthroughs, capital cycles, and intense competition for differentiated platforms.

These transactions are not simply financial events. They are strategic inflection points that define pipelines, platforms, and long-term value creation.

Goodwin sits at the center of this market.

Transformative life sciences deals involve heightened global regulatory, significant governance considerations and antitrust scrutiny, including increasingly complex merger control risk - where FDA pathways, labeling and exclusivity risks, IP freedom-to-operate and licensing terms, and competitive-entry dynamics can drive valuation, structure, and timing. Goodwin’s life sciences M&A team sits close to innovation and is often engaged early to help boards, management teams, and investors shape strategy, evaluate alternatives, and position assets for maximum value, bringing integrated regulatory, IP, and antitrust insight to diligence, deal structuring (including CVRs tied to clinical and regulatory milestones), negotiation strategy, and smart risk allocation to deliver execution certainty. Our life sciences antitrust team works in lockstep with deal counsel to assess competitive risk early, navigate multi-jurisdictional merger control, and help shape transaction strategy to preserve value and execution certainty.

These transactions reflect a clear market reality: strategic buyers competing for next-generation innovation, and companies increasingly using M&A as a core tool for value creation and liquidity.